Targeting Binding Function-3 of the Androgen Receptor Blocks its Co-Chaperone Interactions, Nuclear Translocation, and Activation

The development of new anti-androgens such as enzalutamide or androgen synthesis inhibitors like abiraterone have improved patient outcomes in the treatment of advanced prostate cancer (PCa). However, due to the development of drug resistance and tumor cell survival, the majority of these patients p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: Lallous, Nada, Leblanc, Eric, Munuganti, Ravi S.N., Hassona, Mohamed D.H., Nakouzi, Nader Al, Awrey, Shannon, Morin, Helene, Roshan-Moniri, Mani, Singh, Kriti, Lawn, Sam, Yamazaki, Takeshi, Adomat, Hans H., Andre, Christophe, Daugaard, Mads, Young, Robert N., Tomlinson Guns, Emma S., Rennie, Paul S., Cherkasov, Artem
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5136324/
https://ncbi.nlm.nih.gov/pubmed/27765852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-16-0354
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados